Streetbeat News

Earnings

MSOS

Brady Cobb has announced that his business has been built to achieve positive EBITDA, indicating ongoing efforts and developments behind the scenes. The statement was made in the context of the Cannabis Capital Conference, which is available for live viewing to both existing and new subscribers.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 4:18 pm

CCL

Carnival Corporation (NYSE:CCL) has seen a significant amount of options trading activity, with a bullish sentiment prevailing among investors. Analysis of 16 trades reveals a split, with 62% bullish and 37% bearish expectations. The trading volume and open interest suggest a price target range between $10.0 and $25.0. Notably, options trading volume and open interest have been concentrated within this price band over the last 30 days. Carnival, the world's largest cruise operator, has recovered to its pre-COVID guest levels in 2023. The stock is currently up 1.51% at $14.11, potentially undersold according to RSI readings, with an earnings release anticipated in 68 days. Analysts have set an average target price of $23.0 for Carnival, with ratings ranging from Buy to Overweight.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 4:16 pm

AMX

America Movil's shares have seen an increase following the release of their Q1 earnings report.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 4:12 pm

ABT

EW

Edwards Lifesciences shares are trading lower, potentially due to a negative reaction to Abbott's Q1 earnings report, suggesting a sympathetic market response.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 4:09 pm

SMXT

SolarMax Technology's stock is trading lower following the announcement of its fiscal year 2023 results.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 4:02 pm

LOVE

Analysts' ratings for Lovesac (NASDAQ:LOVE) have shown a shift from bullish to bearish over the last quarter, with a recent average price target of $34.00, down from $39.00. The company's financial performance includes a revenue growth rate of 5.04%, a net margin of 12.36%, an ROE of 15.36%, an ROA of 6.74%, and a debt-to-equity ratio of 0.81, indicating strong profitability and effective asset and debt management.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 4:00 pm

INVO

INVO BioScience, Inc. (NASDAQ:INVO) shares surged after reporting a 396.15% increase in quarterly sales to $1.38 million and remaining on track for profitability in 2024. The company also plans to acquire NAYA Biosciences in an all-stock transaction, aiming to transform into a healthcare services company. INVO's stock is trading above its 200-day moving average, indicating bullish sentiment among investors.

Portfolio Pulse from Erica Kollmann

April 17, 2024 | 3:59 pm

NVS

SNY

Novartis AG (NVS) released data from the ALITHIOS study showing sustained efficacy of Kesimpta in treating relapsing multiple sclerosis for up to six years. The study highlighted significant benefits over Sanofi SA's (SNY) Aubagio, including fewer relapses and MRI lesions, and less disability worsening. Kesimpta's sales nearly doubled to $2.2 billion in fiscal year 2023. NVS shares saw a slight increase of 0.15% to $93.34.

Portfolio Pulse from Vandana Singh

April 17, 2024 | 3:49 pm

SNY

Sanofi SA (NASDAQ:SNY) reported positive Phase 2 study results for its CD40L antibody, frexalimab, in treating relapsing multiple sclerosis. The study showed sustained reduction of disease activity and favorable tolerability after nearly one year. The data revealed significant decreases in lesions and a very low annual relapse rate, with high percentages of patients free of Gd+ T1 lesions at week 48. Frexalimab was well-tolerated, and lymphocyte counts remained stable throughout the study.

Portfolio Pulse from Vandana Singh

April 17, 2024 | 3:37 pm

C

Smart money investors are showing significant interest in Citigroup (NYSE:C) options, with an equal split between bullish and bearish sentiments. Benzinga's options scanner revealed 14 unusual activities, focusing on a price range of $50.0 to $70.0 for Citigroup. The trading volume and open interest analysis suggest a keen market watch on Citigroup's options. Currently, Citigroup's stock is up 2.1%, with a trading volume of 4,584,825 and an RSI indicating a neutral position. The next earnings report is due in 86 days.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 3:31 pm